Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same

Patent metadata

Field	Value
Publication number	US-9469653-B2
Application number	US-201414164616-A
Country	US
Kind code	B2
Filing date	Jan 27, 2014
Priority date	Aug 18, 2011
Publication date	Oct 18, 2016
Grant date	Oct 18, 2016

Abstract

A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

First claim

What is claimed is:

1. A method for treating a degenerative brain disease, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound represented by Formula 1 below, a pharmaceutically acceptable salt, an isomer, a solvate, a hydrate, or a combination thereof,

wherein, in Formula 1 above, R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a hydroxyl group, a substituted or unsubstituted C 1 -C 12 alkyl group, a substituted or unsubstituted C 2 -C 12 alkenyl group, a substituted or unsubstituted C 2 -C 12 alkynyl group, a substituted or unsubstituted C 3 -C 15 cycloalkyl group, a substituted or unsubstituted C 3 -C 40 heterocycloalkyl group, (a substituted or unsubstituted C 6 -C 20 aryl) C 1 -C 12 alkyl group, a substituted or unsubstituted C 1 -C 12 alkoxy group, a substituted or unsubstituted C 6 -C 20 arylamine group, a substituted or unsubstituted C 6 -C 30 diarylamine group, a substituted or unsubstituted C 6 -C 20 aryloxy group, a substituted or unsubstituted C 6 -C 20 aryl group, or a substituted or unsubstituted C 5 -C 20 heteroaryl group; and X is —O—, —S—, or —N(H)—, and
the compound represented by Formula 1 is at least one of N-cyclohexyl-2-phenyloxazolo[5,4-b]pyridine-5-amine, 2-phenyl-5-(pyrrolidine-1-yl)thiazolo[5,4-b]pyridine, 2-(2-chlorophenyl)-5-(pyrrolidine-1-yl)oxazolo[5,4-b]pyridine, 2-(3-chlorophenyl)-5-(pyrrolidine-1-yl)oxazolo[5,4-b]pyridine, 2-(4-fluorophenyl)-5-(pyrrolidine-1-yl)oxazolo[5,4-b]pyridine, 2-phenyl-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 2-phenyl-5-(piperidine-1-yl)thiazolo[5,4-b]pyridine, 2-(2-chlorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 2-(3-fluorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 2-(3-chlorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 3-(5-(piperidine-1-yl)oxazolo[5,4-b]pyridine-2-yl)benzonitrile, 2-(4-fluorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 2-(4-bromophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine, 2-(3-chlorophenyl)-N-methyloxazolo[5,4-b]pyridine-5-amine, or 2-(4-chlorophenyl)-N-methyloxazolo[5,4-b]pyridine-5-amine.

2. The method of claim 1 , wherein the degenerative brain disease is selected from the group consisting of Alzheimer's disease, mild cognitive impairment, vascular dementia, frontotemporal dementia, Louis corpuscle dementia, Creutzfeld-Jakob disease, traumatic head injuries, syphilis, acquired immune deficiency syndrome (AIDS), viral infection, brain abscess, brain tumor, dementia in metabolic disease, hypoxia, Parkinson's disease, Huntington's disease, Pick's disease, epilepsy, ischemia, stroke, attention deficit hyperactivity disorder (ADHD), schizophrenia, depression, manic-depression, and stress disorder.

Assignees

• Korea Inst Sci & Tech

Inventors

• Lee Changjoon Justin
• Jo Seonmi
• Yoon Boeun
• Choo Hyunah
• Kim Ji Yoon
• Kim Daesoo

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P31/12

  Antivirals · CPC title